TrialBlood advances2023

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.

Ryan C Lynch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.